Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NBL-020
- Development stage
- Phase 1
- Lead developer
- NovaRock Biotherapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
NBL-020 is a fully human monoclonal antibody that targets tumor necrosis factor receptor superfamily member 1B (TNFR2; also known as TNFRSF1B), a member of the TNF receptor superfamily. Developed using NovaRock Biotherapeutics' proprietary AFIS platform, NBL-020 acts as an antagonist to TNFR2, blocking its signaling and thereby modulating the immune response within the tumor microenvironment. By inhibiting TNFR2, which is highly expressed on regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), NBL-020 reduces immunosuppression and enhances antitumor immunity. Preclinical studies have shown that it can inhibit tumor growth and prolong survival both as a single agent and in combination with anti-PD1 antibodies, including in models resistant to PD-1/PD-L1 inhibitors. The drug is currently being evaluated in Phase 1 clinical trials for advanced malignant solid tumors.
- Other names
- anti-TNFR2 monoclonal antibody NBL-020anti-TNFR-2 monoclonal antibody NBL-020anti-TNFR 2 monoclonal antibody NBL-020
02
Targets
TNFR2 (Tumor necrosis factor receptor superfamily member 1B)
Beyond the preview
Go deeper on NBL-020.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NBL-020.